Research programme: hypoxia inducible factor-proline dioxygenase inhibitors - Akebia TherapeuticsAlternative Names: AKB 6899
Latest Information Update: 07 Jan 2016
At a glance
- Originator Akebia Therapeutics
- Class Small molecules
- Mechanism of Action Hypoxia-inducible factor-proline dioxygenase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer; Eye disorders; Inflammatory bowel diseases